Medical
Resume:
CURRICULUM VITAE
Name: Xin Wei Wang
Ph.D.
Business Address: Laboratory of Human Carcinogenesis
NIH, NCI
Building 37, Room 3044A
Bethesda, MD 20892-4255
Tel: 301-***-****
Fax: 301-***-****
Email: aboqu6@r.postjobfree.com
Internet: http://ccr.cancer.gov/staff/staff.asp?profileid=5764
Education:
B.S., Shanghai First Medical College 1982
M.S., Chinese Academy of Sciences 1984
Ph.D., New York University 1991
Post Graduate Education
Postdoctoral Fellowship in cell biology 19911992
Roche Institute of Molecular Biology
Nutley, New Jersey
IRTA Fellowship in molecular carcinogenesis1992-1995
National Cancer Institute, National Institute of Health
Bethesda, Maryland
Employment History
Research Scientist of Institute of Environmental Medicine 1986-1987New York University Medical Center, Tuxedo, New York
Senior Staff Fellow of Laboratory of Human Carcinogenesis1995-1998National Cancer Institute, NIH, Bethesda, Maryland
Investigator and Head of Liver Carcinogenesis Section1998-2005Laboratory of Human Carcinogenesis, NCI, Bethesda, Maryland
Adjunct Associate Professor2002-2005University of Maryland Cancer Center, Baltimore, Maryland
Adjunct Professor2005-presnetUniversity of Maryland Cancer Center, Baltimore, Maryland
Senior Investigator2005-present
Chief, Liver Carcinogenesis Section
LHC, CCR, NCI, NIH, Bethesda, Maryland
Professional Societies:
American Association for Cancer Research (member)
American Association for the Advancement of Science (member)
CCR-NCI HIV and Cancer Virology Faculty (members): CCR-NCI Cellular, Molecular and
Developmental Biology Faculty; CCR-NCI Genetics, Genomics, and Proteomics Faculty; CCR-NCI
Gene Expression Faculty; CCR-NCI Bioinformatics, Biostatistics and Computational Biology
Faculty; CCR-NCI Molecular Targets Faculty; Gastrointestinal Malignancies Faculty;
Metastasis Working Group
International Society of Gastroenterological Carcinogenesis (Board of Directors)
Society of Chinese Bioscientists in America (member)
International Liver Cancer Association (Founding member)
Honors and Awards
Shanghai First Medical College Best Student Award 1980
Committee of Pharmaceutics Sinica Best Thesis Award 1984
Travel award, American Society of Toxicology 1988
Meritorious Research Award, American Society of Toxicology 1991
Roche Institute of Molecular Biology Fellowship 1991
NCI CRTA fellowship 1992-1995
NIH Technology Transfer Award 1998
NIH Technology Transfer Award 2000
NIH Technology Transfer Award 2002
NIH Technology Transfer Award 2003
NIH Technology Transfer Award 2004
Visiting professor, Mount Sinai School of Medicine 2004
NIH Technology Transfer Award 2005
Distinguished lecturer, UMBC Greenebaum Cancer Center 2005
NIH Technology Transfer Award 2006
NIH Technology Transfer Award 2007
NIH Technology Transfer Award 2008
Natural Sciences Award (first place), The Ministry of Education of
the PeopleOs Republic of China 2008
NIH Technology Transfer Award 2009
NIH Merit Award 2009
NCI Outstanding Mentor Award (Mentor of Merit) 2009
Administrative Service
Institutional Service
NIH FARE Judge 2001, 2002, 2004,
2005, 2006
Member, NCI-UMD Tissue Resource Review Panel 2000, 2005
Chair, LHC Microarray Interest Group 2002-present
Member, NIH-NCI HCC Clinical Steering Committee 2005-present
CCR-NCI Inflammation and Cancer Initiative Discussion 2005
Member, CCR-NCI Strategic Plan: focus group 2006
Member of Steering committee, the Center of Excellence in Integrative Cancer Biology and
Genomics (CEICBG), CCR, NCI 2007
Co-chair, the biomarkers and molecular targets subgroup, CEICBG 2007
Ad hoc reviewer, NCI Quadrennial Review of Staff Scientists 2008
Member, NCI CCR Advisory Board (CAB) 2008-present
National Service
Organizer, International Workshop on Human
Hepatocellular Carcinoma, Bethesda, Maryland 2002
The International Society of Gastroenterological
Carcinogenesis (Board of Directors) 2003-2005
NRC Research Advisor 2005-present
Co-organizer, NCI-cosponsored Symposium on liver cancer
At the Shanghai-Hong Kong Liver Congress March 2006
Co-organizer, Keystone Symposia, Beijing, China 2007
Peer Review Committee Ad-hoc Member, ACS 2007-2008
Co-organizer, US-Sino Symposia on Liver Cancer 2008
Member, Poster Review Committee, 2nd ILCA Conference 2008
Peer Review Committee on Tumor Biology and Genomics
2009-2012Editorial board
Carcinogenesis2002-2005
Liver Cancer Review Letters2008-present
Hepatology 2008-presentGrant reviewer
Cancer Research Campaign1998-2000
Cancer Research UK2003-present
Jeffress Memorial Trust2001
Italian Association for Cancer Research 2003-present
Research Grants Proposal of Hong Kong 2004-present
NIAID, NIDDK, review panels 2006-
ACS Study Section on Tumor Biology and Genomics 2007-present
The Challenge Grant RFA 2009
Editorial services (Add-Hoc Reviewer
)
1995-present
(Listed major journals with impact factors >10 from over 30 journals)
Cell
Cancer Cell
Gastroenterology
Genes & Development
Immunity
Journal of Clinical Investigation
Journal of National Cancer Institute
Hepatology
New England Journal of Medicine
Proc. Natl. Acad. Sci. USA
Teaching Service
Preceptor, HHMI-NIH Research Scholars Program:
1994-1995Heidi Yeh, MD (University of Pennsylvania
)
1995-1996Michael Gibson, MD (University of Maryland
)
1996-1997Nissim Khabie, MD
(Mayo clinics)
1997-1998Anne Manicone, MD (University of Washington
)
2003-2004Brian Zipser, MD (Brown University
)
2006-2008Giang Nguyen (Albany Medical College
)
2007-2008Fei Dong
(Case Western Reserve University School of Medicine)
2008-2009Xiaoyu Liang (Georgetown University)
Guest lecturer, the Topics in Molecular Epidemiology course
Georgetown University Medical School2000-2004Thesis Advisor
:
1996Jill Coursen, MS, Hood College
2002 Qinghai Ye, MD/PhD, Shanghai Medical University
2006 Huliang Jia, MD/PhD, Fudan University
2007 Guoling Lin, MD/PhD, Fudan University
2008 Jiong Shi, MD/PhD, Fudan University
Thesis Committee:
1999Joo-Yeon Yoo, PhD, University of Maryland
Current Lab members:
Marshonna Forgues, BA (1998-), Lab technician
Anuradha Budhu, PhD (2002-), Staff Scientist
Zhipeng Yu, BA (2006-), Lab technician
Junfang Ji, MD/PhD (2006-), Postdoctoral fellow
Steffi Roessler, PhD (2006-), Postdoctoral fellow
Xuelian Zhao, PhD (2008-), Postdoctoral fellow
Mia R Kumar, BA (2009-) Post-Baccalaureate Fellow
Former Lab members
:
Jill D. Coursen, MS (1997-1998), Research Scientist II, Genta Incorporated
Ann Tseng, MD (1998-1999), Assistant professor, Oregon Health & Science University
Chuan-
Ging Wu, MD/PhD (1998-2001), Staff Scientist, FDA
Haress Rahim, DDS (1999), Dentist, Dental Arts Center
Lily Wong (1999, 2000)
Michele Abbasi (2000)
Teh-Ia Huo, MD (2000-2001), Professor, Yang Ming University
David M. Salvay, MS (2000), Graduate student, Northwestern University
Jin Woo Kim, PhD (2001-2004), Assistant Professor, Wake Forest University
School of
Medicine
Jessica Sime, PhD (2001-2002), Northwestern University Medical School
Alice Uy (2000, 2001)
Shabina Siddique, MD (2000, 2001), Resident, Johns Hopkins University
Qinghai Ye, MD/PhD (2002), Professor, Liver Cancer Institute, Shanghai
Lavanya Viswanathan (2002)
Wei Wang, PhD (2003-2005), Staff Scientist, FDA
Siritida Porntosapon, PhD (2005), Chulabhorn Research Institute, Thailand
Supornrat Pulleium, BA (2005), Chulabhorn Research Institute, Thailand
Vivian Takafuji, PhD (2004-2006), Physical therapist
Mi Jung Lim, PhD (2005-2006), Senior Scientist, Biology Laboratory, South Korea
Nicholas Younes (2005), undergraduate student,
Huliang Jia, MD/PhD (2005-2006), Assistant Professor, Liver Cancer Institute, Shanghai
Mindy Wei (2006), Undergraduate student, University of Maryland
Andy Chen (2006), Undergraduate student
Bhumi Patel (2006, 2007), Premed student,
Louie Zhou (2007), Premed student, University of Pennsylvania
Lei Zhao, MD/PhD (2007-2008), Associate professor, Shandong Provincial Tumor Hospital and
Institute of Oncology
Guoling Lin, MD (2007-2008), Assistant Professor, Zejiang University
Fei Dong (2007-2008), Case Western Reserve University School of Medicine
Taro Yamashita, MD/PhD (2005-2008), Assistant Professor, Kanazawa University
Jiong Shi, MD/PhD (2008-2009), Visiting fellow
Xiaoyu Liang (2009), Graduate student, Georgetown University
Vinay Rao, BA (2008-2009), Kirksville College of Osteopathic Medicine
Grant Support
Principal Investigator 1998-2000
Mechanism of Human liver carcinogenesis.
DBS Budget Allocation, NCI, NIH
Principal Investigator 2000-present
Mechanism of Human liver carcinogenesis.
CCR Budget Allocation, NCI, NIH
Additional Competitive Funds:
Principal Investigator 2001
SAGE transcript profiles. DBS, NCI, NIH;
Total direct costs awarded: $40,000
Principal Investigator 2001
Molecular profiling of metastatic hepatocellular carcinoma. DBS, NCI
Total direct costs awarded: $19,500
Principal Investigator 2001
Program travel. DBS, NCI, NIH
Total direct costs awarded: $15,000
Principal Investigator 2002
International Workshop. CCR, NCI, NIH,
Total direct costs awarded: $25,000
Principal Investigator 2002
International Workshop. NIH Office of Rare Diseases
Total direct costs awarded: $20,000
Principal Investigator 2003
Program travel. CCR, NCI, NIH
Total direct costs awarded: $15,000
Principal Investigator 2004
Program travel. CCR, NCI, NIH
Total direct costs awarded: $15,000
Principal Investigator 2005
Gene expression profiling of HCC by microarray
Total direct costs awarded: $60,000
Principal Investigator 2005
MicroRNA expression profiling of HCC
Total director costs awarded: $90,000
Principal Investigator 2006
Program travel. CCR, NCI, NIH
Total direct costs awarded: $15,000
Principal Investigator 2006
Affymetrix HTA analysis of HCC
Total director costs awarded: $50,000 (ODRS support)
Principal Investigator 2007
Program travel. CCR, NCI, NIH
Total direct costs awarded: $15,000
Principal Investigator 2007
Acquisition of ABI 7900HT Fast Real-Time PCR System
Total direct costs awarded: $90,000
Principal Investigator 2008
Co-sponsorship of Sino-US joint symposium in ILC
Total direct costs awarded: $30,000
Patents and Inventions
U.S. Patent No. 5,985,829. Screening assays for compounds that cause apoptosis.
U.S. Patent No. 6,613,318. Methods for identifying inhibitors of Gadd45.
U.S. PHS Employee Invention. The Establishment of telomerase-immortalized human liver
epithelial cell lines.
PCT Patent application, 60/370,895 (2002). Methods of diagnosing potential for metastasis
or developing hepatocellular carcinoma or identifying therapeutic targets.
U.S. Patent application (2005). Compositions and Methods for Diagnosis and Treatment of
Metastatic Disease.
U.S. Patent application, 60/732,332 (2005). Method of Screening for hepatocellular
carcinoma.
U.S. Patent application (2006). A novel diagnostic and therapeutic strategy for
metastatic hepatocellular carcinoma by targeting a unique region of osteopontin.
U.S. Patent application (2006). Methods of determining the prognosis of an
adenocarcinoma.
Provisional Patent application, 60/884,052 (2006). Methods of determining the prognosis
of hepatocellular carcinoma.
Provisional Patent application, 60/942,833 (2007). Methods for determining hepatocellular
carcinoma subtype and detecting hepatic cancer stem cells.
Provisional Patent application, 61/131,800 (2008). Use of microRNA-26 as a predictive
marker for hepatocellular carcinoma clinical outcome and response to interferon therapy.
Provisional Patent application, 61/198,813 (2008). Gene signature for predicting
hepatocellular carcinoma patient prognosis
Major Invited Speeches or Talks
1. ORole of TGFb1 in cell growth regulationO. NCI, Bethesda, MD, May 1992
2. OHBV and liver cancerO. Life Sciences Symposium on Human Genetics, Association for
Chinese Scientists in America, the Great Washington Chapter, April 1993
3. OFunctional interaction between p53 and TFIIHO. INSERM Unit,
University of Strasbourg,
Strasbourg, France, May 19944. ORole of p53 in DNA repair and apoptosisO. Department of Cell Biology and Genetics,
Medical Genetics Center, Erasmus University, Rotterdam, Netherlands, August 19945. OFunctional interaction between p53 and TFIIHO. Symposium on DNA Repair and Human
Syndrome, NIH Research Festivals, September 1994
6. OFunctional interaction between p53 and TFIIHO. DNA repair interest group, NIH,
Bethesda, MD, March 1995
7. OFunctional interaction between p53 and TFIIHO. Genetic Susceptibility and Molecular
Carcinogenesis, AACR, Keystone, January 1996
8. OFunctional interaction between p53 and HBxO. 1996 Shanghai International Symposium on
Liver Cancer & Hepatitis, Shanghai, China, May 19969. OFunctional interaction between p53 and TFIIHO. Department of Pathology & Oncology,
University of Maryland Cancer Center, Baltimore, MD, May 199610. OFunctional interaction between p53 and TFIIHO. IASLC Workshop, Nancy, France, July
1996
11. Op53 and TFIIHO. Symposium on apoptosis, Scanning Microscopy International, Chicago,
IL, May 1997
12. ORole of Gadd45 in G2/M cell cycle checkpoint controlO. Cancer genetics and tumor
suppressor genes conference,
Frederick, MD, July 199713. Op53 and genomic instabilityO. National Cancer Institute,
Bethesda, MD, September
199714. Op53, DNA helicases and genomic instabilityO. XVIII International Congress of
Genetics,
Beijing, China, August 199815
. Op53, DNA helicases and genomic instabilityO. The 5th International Symposium on
Dendritic Cells in Fundamental Clinical Immunology,
Pittsburgh, PA, November 199816
. Op53, DNA helicases and genomic instabilityO. The National Capital Area Branch of the
Society for In Vitro Biology, Beltsville, MD, December 199817
. ONuclear-cytoplasm trafficking and oncogenesisO. The 14th Aspen Cancer Conference,
Aspen, CO, July 199918. Op53 and Bloom syndromeO. Symposium on DNA Repair and Apoptosis, NIH Research
Festivals, Bethesda, MD, September 199919. ORole of Gadd45 in G2/M cell cycle checkpoint controlO. Department of Biochemistry
and Molecular Biology,
University of Maryland, Baltimore, MD, March 200020. ONuclear-cytoplasm trafficking and oncogenesisO. Graduate Class for Topics in
Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center,
Washington, DC, May 200021. ONuclear-cytoplasm trafficking and oncogenesisO. Department of Pathology,
Virginia
Commonwealth University, Richmond, VA, September 200022. OMolecular profiling of human hepatocellular carcinomaO. Graduate Class for Topics in
Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center,
Washington, DC, April 200123. OMolecular pathogenesis of liver cancerO. The 9th International Congress of
Toxicology, Brisbane, Australia, September 2001
24. ONucleocytoplasmic transport, spindle assembly and chromosomal stabilityO. The 16th
Aspen Cancer Conference, Aspen, CO, July 2001
25. OMolecular profiling of human hepatocellular carcinomaO. Multicenter Hemophilia
Cohort Study-II, Washington, DC,
January 200226. OMolecular profiling of human hepatocellular carcinomaO. Molecular Genomics 2002:
profiling of gene expression, Galveston, TX, 2002
27. OMolecular profiling of human hepatocellular carcinomaO. Graduate Class for Topics in
Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center,
Washington, DC, March 200228
. OMolecular profiling of human hepatocellular carcinomaO. Clinical Center, NIH,
Bethesda, MD, May 200229. OMolecular profiling of human hepatocellular carcinomaO. FASEB Summer Research
Conference on "Mechanisms of Liver Growth, Differentiation and Molecular Pathogenesis of
Hepatic Diseases, Snow Mass, CO, July 2002
30. OMolecular profiling of human hepatocellular carcinomaO. International Workshop on
Human Hepatocellular Carcinoma, Bethesda, MD, September 2002
31. OMolecular pathogenesis of human hepatocellular carcinomaO. Liver Cancer Institute
and Zhongshan Hospital, Fudan University, Shanghai, China, October 2002
32. OMolecular pathogenesis of human hepatocellular carcinomaO. Cancer
Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China October 2002
33. OMolecular profiling of human hepatocellular carcinomaO. Thomas Jefferson University,
Jefferson Center for Biomedical Research, Doylestown, PA, January 2003
34. OMolecular pathogenesis of human hepatocellular carcinomaO. Bernie Carter Center for
Immunology Research,
University of Virginia Health Sciences Center, Charlottesville, VA.
March 2003
35. OLesson learned from molecular profiling of human hepatocellular carcinomaO. Graduate
Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University
Medical Center, Washington, DC, May 2003
36. OLesson learned from molecular profiling of human hepatocellular carcinomaO. The
Thirteenth International Symposium of Hiroshima Cancer Seminar, Hiroshima, Japan, October
2003.
37. OLesson from molecular profiling of human hepatocellular cancerO. Symposium on
molecular diagnosis of human cancer sponsored by Shanghai Medical Association, Shanghai,
China, November 2003.
38. OLesson learned from molecular profiling of human hepatocellular cancerO. The GW
Cancer Institute, the George Washington University Medical Center, Washington DC, January
2004.
39. OLesson learned from molecular profiling of human hepatocellular carcinomaO. Hong
Kong-Shanghai International Liver Congress 2004, Hong Kong, China, February 2004.
40. OMetastatic signature of hepatocellular cancerO. The 19th Aspen Cancer Conference,
Aspen, Colorado, August 2004.
41. OMolecular signature of liver cancer metastasisO. The 3rd International Conference on
Gastroenterological Carcinogenesis, Sapporo, Japan, August 2004.
42. OMolecular profiling of chronic liver diseases and hepatocellular cancerO. The 35th
Environmental Mutagen Society Annual Meeting, Pittsburgh, Pennsylvania, October 2004.
43. OMolecular profiling of chronic liver diseases and hepatocellular cancerO. Guest
speaker, Division of Gastroenterology and Liver Diseases, Mount Sinai School of Medicine;
New York, New York, October 2004.
44. Keystone Symposia Program Committee Meeting (as an ad hoc member), Keystone,
Colorado, January 2005.
45. Frontiers in Oncology Seminar Series: OProgress on molecular diagnosis and molecular
targets for human hepatocellular carcinomaO. Distinguished lecturer, University of
Maryland Greenebaum Cancer Center, Baltimore, MD, March 2005.
46. OMolecular signatures of metastatic hepatocellular carcinomaO. Invited speaker, The
National Cancer Institute Liver Cancer Symposium, Bethesda, MD, April 2005
47. OMetastatic signature of hepatocellular carcinomaO in New Concepts in Organ-Site
Research. Invited speaker, The 96th Annual Meeting of the American Association for Cancer
Research, Anaheim, CA, April 2005
48. OCytokines in human hepatocellular carcinomaO. Invited speaker, The NCI inflammation
and liver cancer conference, Bethesda, MD, December 2005
49. OHepatocellular Carcinoma: State-of-the-Art on molecular diagnosis and therapeutic
opportunityO. Speaker and co-organizer, NCI Symposium, Shanghai-Hong Kong International
Liver Congress 2006, Shanghai, China, March 2006
50. ORole of liver microenvironment in metastasisO. Invited speaker, CNIO Cancer
Conference, Madrid, Spain, May 2006
51. OLiver microenvironment and hepatocarcinogenesisO. Invited speaker, the 4th
International Society of Gastroenterological Carcinogenesis Conference, Hawaii, August
2006
52. OInflammation, cytokines and hepatocellular carcinomaO. Invited speaker, The GTCbio
5th annual conference on Cytokines and Inflammation, Breckenridge, CO, January 2007
53. OThe art of liver cancer prognosis: from the view point of biologyO in New Concepts
in Organ-Site Research. Invited speaker, The 96th Annual Meeting of the American
Association for Cancer Research, Los Angeles, CA, April 2007
54. OHepatocellular Carcinoma: A Genomic PerspectiveO. Invited speaker, Center for Human
Genomics Seminar Series, Wake Forest University School of Medicine, May, 2007
55. OInterrogating the genome in hepatocellular carcinomaO. Invited speaker, Cancer
Genetics and Epidemiology Program Monthly Seminar Series, the Lombardi Cancer Center at
Georgetown University, Washington, DC, June 200756. OInterrogating the genome in hepatocellular carcinomaO. Invited speaker, National
Institute for Occupational Safety and Health Seminar, CDC, Morgantown, WV; August 22, 2007
57. OInflammatory architects of metastatic hepatocellular carcinomaO. Invited speaker,
Annual symposium of the NCI Center of Excellence in Immunology, Bethesda, MD, October,
2007
58. ODiagnostic and prognostic signatures of liver cancerO. Co-organizer and speaker,
Keystone Symposia on GI cancer,
Beijing, China, October 200759. OHepatocellular carcinoma: a genomic perspectiveO. Invited speaker, UMMS
Immunobiology and Transplantation Biology Research Conference, November, 2007
60. OLiver cancer heterogeneity, cellular origin and cancer stem cellsO. Invited speaker,
NIAAA, DICBR, Rockville, MD, March 200861. OWhat makes liver cancer so deadlyO in New Concepts in Organ-Site Research. Invited
speaker, The 97th Annual Meeting of the American Association for Cancer Research, San
Diego, CA, April 2008
62. OGenomic perspectives of liver cancerO. NCI CCR Grand Rounds speaker, May 2009
63. OLiver Cancer: biology and clinical practiceO. Invited speaker, Chulabhorn Research
Institute, Thailand, June 2008
64. ORegulation of hepatic cancer stem cellsO. Invited speaker, Sino-US Joint Symposium,
International Liver Congress, June 2008
65. OInflammation and liver cancerO. Invited speaker, 2008 International Liver Congress,
June 2008.
66. OGenomic perspectives of liver cancerO. Keynote speaker, Chinese Medical Association
Annual Meeting, Taipei, June 2008.
67. OLiver cancer heterogeneity and cancer stem cellsO. Invited speaker, Institute of
Clinical Medicine, National Yang-Ming University School of Medicine Taipei, Taiwan, June
2008.
68. Department of GI Medical Oncology, University of Texas M.D. Anderson Cancer Center,
Houston, July 2008.
69. OThe origin of liver cancerO. Invited speaker, 5th ISGC Conference, Oxford, England,
Sept 2008.
70. OThe role of microRNAs in human hepatocellular carcinomaO. Invited speaker, The NIH
Research Festival, October, 2008.
71. OChronic inflammation and hepatocellular carcinomaO. Invited speaker, Liver and
colorectal cancer: molecular biology and clinical research CIBERebd, Barcelona, February
2008
72. OGenome-based molecular predictors of human hepatocellular carcinomaO. Invited
speaker, Symposium on Frontiers in Liver Cancer Prevention, Diagnosis, Prognosis and
Treatment, Bangkok, Thailand, February 2009
73. OMolecular profiling-insights into the pathogenesis of HCCO in New Concepts in Organ-
Site Research. Invited speaker, The 98th Annual Meeting of the American Association for
Cancer Research, Denver, CO, April 200974. ORole of microRNA in hepatocellular cancerO. ILCA/AACR joint symposium, AACR annual
meeting. Denver, CO, April, 2009.
75. OmicroRNAs in hepatocellular cancerO. Invited speaker, The NCI Cancer and
Inflammation Program Retreat. Gettysburg, PA, May 2009
76. OMolecular Diagnosis and Prognosis of Hepatocellular CarcinomaO. Speaker and
Organizer; The Second International Workshop on Primary Liver Cancer, Potomac, MD,
October, 2009
BIBLIOGRAPHY
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional
activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91: 2230-
2234, 1994.
15. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M., Wang, Z.,
Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H.
J., Forrester, K. and Harris, C. C.: p53 modulation of TFIIH associated nucleotide
excision repair activity. Nature Genetics 10: 188-195, 1995.
16. Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Wang, X. W. and Harris, C. C.:
Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Oncogene 10: 2103-2111, 1995.
17. Wang, X. W., Gibson, M., Vermulen, W., Yeh, H., Forrester, K., Sturzbacher, H.-W.,
Hoeijmakers, J. H. J. and Harris, C. C.: Abrogation of p53-induced apoptosis by the
hepatitis B viral X gene. Cancer Res 55: 6012-6016, 1995.
18. Forrester, K., Ambs, S., Lupold, S. E., Kapust, R. B., Spillare, E. A., Weinberg,
W.C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Billiar, T. R. and Harris, C. C.:
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase
(NOS2) expression by wild-type p53. Proc Natl Acad Sci USA 93: 2442-2447, 1996.
19. Wang, X. W., Vermulen, W., Coursen, J. D., Gibson, M. J., Lupold, S. E., Forrester,
K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H. J. and Harris, C. C.: The XPB and XPD
DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10: 1219-
1232, 1996.
20. Xu, G. W., Sun, Z. T., Forrester, K., Wang, X. W., Coursen, J. D. and Harris, C.C.:
Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular
carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 24:
1264-1268, 1996.
21. Wang, X. W. and Harris, C. C.: TP53 tumor suppressor gene: clues to molecular
carcinogenesis and cancer therapy. Cancer Surveys 28: 169-196, 1996.
22. Adler, V., Pincus, M. R., Minamoto, T., Fuchs, S. Y., Bluth, M. J., Brandt-Rauf,
R.W., Friedman, F. K., Robinson, R. C., Chen, J. M., Wang, X. W. Harris, C. C. and Ronai,
Z.: Conformation-dependent phosphorylation of p53. Proc Natl Acad Sci USA 94: 1686-1691,
1997.
23. Buchhop, S., Gibson, M. K., Wang, X. W., Wagner, P., Sturzbecher, H.-W. and Harris,
C. C.: Interaction of p53 with the human Rad51 protein. Nucleic Acid Res 25: 3868-3874,
1997.
24. Wang, X. W. and Harris, C. C.: p53 modulation of cell cycle and apoptosis. Scanning
Microscopy 11: 953-965, 1997.
25. Wang, X. W. and Harris, C. C.: p53 tumor-suppressor gene: clues to molecular
carcinogenesis. J Cell Physiol 173: 247-255, 1997.
26. Elmore, L. W., Hancock, A. R., Chang, S.-F., Wang, X. W., Chang, S., Callahan, C. P.,
Geller, D. A., Will, H. and Harris, C. C.: Hepatitis B virus X protein and p53 tumor
suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 94: 14707-
14712, 1997.
27. Parekh, T. V., Wang, X. W., Makri-Werzen, D. M., Greenspan, D. S. and Newman, M. J.:
Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the
inhibitory effects of TGF-1. Cell Growth & Differ 9: 423-433, 1998.
28. Jia, L., Wang, X. W. and Harris, C. C.: Hepatitis B virus X protein inhibits
nucleotide excision repair. Int J Cancer 80: 875-879, 1999.
29. Zhan, Q., Antinore, M. J., Wang, X. W., Carrier, F., Smith, M. L., Harris, C. C. and
Fornace, A. J. Jr: Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity
by the p53-regulated protein Gadd45. Oncogene 18: 2892-2900, 1999.
30. Zhou, X., Wang, X. W., Xu, L., Hagiwara, K., Nagashima, M. and Harris, C. C.:
Cterminal domain (CTD) of p53 is involved in p53mediated apoptosis and transcriptional
transactivation. Cancer Res 59: 843-848, 1999.
31. Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C.,
Ried, T. and Deng, C. X.: Centrosome amplification and a defective G2/M checkpoint induce
genetic instability in BRCA1 exon 11 isoform-deficient mice. Mol Cell 3: 389-395, 1999.
32. Wang, X. W., Coursen, J. D., Zhan, Q., Fornace, A. J., Jr and Harris, C. C.: GADD45
induction of a G2-M cell cycle checkpoint. Proc Natl Acad Sci USA 96: 3706-3711, 1999.
33. Robles, A. I., Wang, X. W. and Harris, C. C.: Drug-induced apoptosis is delayed and
reduced in XPD lymphoblastoid cell lines: possible role of p53 interaction with TFIIH in
the induction of apoptosis. Oncogene 18: 4681-4688, 1999.
34. Spillare, E. A., Robles, A. I., Wang, X. W., Shen, J-C., Yu, C-E., Schellenberg, G.
D. and Harris, C.C.: p53-mediated apoptosis is attenuated in Werner Syndrome Cells. Genes
Dev 13: 1355-1360, 1999.
35. Mazur, S. J., Sakaguchi, K., Appella, E., Wang, X. W., Harris, C. C. and Bohr, V. A.:
Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA
involves the C-terminal domain. J Mol Biol 292: 241-249, 1999.
36. Wang, X. W.: Role of p53 and apoptosis in carcinogenesis. Anticancer Res 19: 4759-
4771, 1999.
37. Yoo, J. Y., Wang, X. W., Rishi, A. K., Lessor, T., Xia, X. M., Gustafson, T. A. and
Hamburger, A. W.: Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of
this binding by heregulin. Br J Cancer 82: 683-690, 2000.
38. Yang, Q., Manicone, A., Coursen, J. D., Linke, S. P., Nagashima, M., Forgues, M., and
Wang, X. W. Involvement of a unique acidic motif (DEDDDR) in a GADD45-medicated G2/M
Checkpoint. J Biol Chem 275: 368**-*****, 2000.
39. Liu, J., Akoulitchev, S., Weber, A., Ge, H., Chuikov, S., Libutti, D., Wang, X.W.,
Conaway, J.W., Harris, C.C., Conaway, R.C., Reinberg, D. and Levens, D. Defective
interplay of activators and repressors with TFIIH in Xeroderma Pigmentosum. Cell 104: 353-
363, 2001.
40. Huo, T-I, Wang, X.W., Forgues, M., Wu, C-G, Spillare, E. A., Giannini, C., Brechot,
C. and Harris, C.C. Hepatitis B virus X mutants derived from human hepatocellular
carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 20: 3620-3628,
2001.
41. Brosh, R.M. Jr., Karmakar, P., Sommers, J.A., Yang, Q., Wang, X.W., Spillare, E.A.,
Harris, C.C. and Bohr, V.A. p53 modulates the exonuclease activity of Werner syndrome
protein. J Biol Chem 276: 350**-*****, 2001.
42. Wang, X.W., Tseng, A., Ellis, N. A., Spillare, E. A., Linke, S. P., Robles, A.I.,
Seker, H., Yang, Q., Hu, P., Beresten, S., Bemmels, N.A., Garfield, S. and Harris, C. C.
Functional interaction of p53 and BLM DNA helicase in apoptosis. J Biol Chem 276: 32948-
32955, 2001.
43. Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S.P., Pedeux, R., Wang,
X.W., Yokota, J., Riabowol, K. and Harris, C.C. DNA damage-inducible gene p33ING2
negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA
98: 9671-9676, 2001.
44. Wu, C-G, Salvay, D.M., Forgues, M., Valerie, K., Farnsworth, J., Markin, R.S. and
Wang, X.W. Distinctive gene expression profiles associated with hepatitis B virus X
protein. Oncogene 20: 3674-3682, 2001.
45. Forgues, M., Marogi, A., Wu, C., Spillare, E., Yang, Q., Yoshida, M., Wang, X.W.
Involvement of Crm1-mediated nuclear export in hepatitis B virus HBx-mediated
transactivation. J Biol Chem 276: 227**-*****, 2001.
46. Wang, X.W. Microinjection technique used to study functional interaction between p53
and hepatitis B virus X gene in apoptosis. Mol Biotechnol 18: 169-177, 2001.
47. Wang, X.W., Hussain, S.P., Huo, T-I, Wu, C-G., Forgues, M., Hofseth, L.J., Brechot,
C., Harris, C.C. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-
182: 43-47, 2002 (The top ten of most downloaded articles within the toxicology category
of all articles published in Elsevier journals in 2003).
48. Staib, F., Hussain, S.P., Hofseth, L.J., Wang, X.W. and Harris, C.C.: p53 and liver
carcinogenesis. Human Mutation 21, 201-216, 2003.
49. Yang, Q., Zhang, R., Wang, X.W., Spillare, E.A., Linke, S.P., Subramanian, D.,
Griffith, J.D., Li, J-L, Hickson, I.D., Shen, J.C., Loeb, L.A., Mazur, S.J., Appella, E.,
Brosh, R.M., Karmakar, P., Bohr, V.A., Harris, C.C. The processing of holliday junctions
by BLM and WRN helicases is regulated by p53. J Biol Chem 277: 319**-*****, 2002.
50. Wu, C-G, Forgues, M., Siddique, S., Farnsworth, J., Kristoffer, V., Wang, X.W.: SAGE
transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B
virus X protein. FASEB J 16: 1665-7, 2002.
51. Linke, S.P., Sengupta, S., Khabie, N., Jeffries, B.A., Buchhop, S., Miska, S.,
Henning, W., Pedeux, R., Wang, X.W., Hofseth, L.J., Yang, Q., Garfield, S.H., Sturzbecher,
H.-W., and Harris, C.C. (2003). p53 interacts with hRAD51 and hRAD54, and directly
modulates homologous recombination. Cancer Res 63, 2596-2605, 2003.
52. Kim, J.W. and Wang, X. W. Gene expression profiling of preneoplastic liver disease
and liver cancer: a new era for improved early detection and treatment of these deadly
diseases? Carcinogenesis 24, 363-369, 2003.
53. Ye, Q.H., Qin, L.X., Forgues, M., He, P, Kim, J.W., Peng, A.C., Simon, R., Li, Y.,
Robles, A.I., Chen, Y., Ma, Z.C, Wu, Z.Q, Ye, S.L., Liu, Y.K., Tang, Z.Y. and Wang, X.W.
Predicting Hepatitis B Virus-Positive Metastatic Hepatocellular Carcinomas Using Gene
Expression Profiling and Supervised Machine Learning. Nat Med 9, 416-423, 2003.
54. Forgues, M., Difilippantonio, M.J., Linke, S.P., Ried, T., Nagashima, K., Feden, J.,
Valerie, K., Fukasawa, K., Wang, X.W. Involvement of Crm1 in HBx-induced aberrant
centriole replication and abnormal mitotic spindles. Mol Cell Biol 23, 5282-5292, 2003.
55. Ashktorab, H., Ahmed, A., Littleton, G., Wang, X.W., Allen, C.R., Tackey, R.,
Walters, C., Smoot, D.T. p53 and p14 increase sensitivity of gastric cells to H. pylori-
induced apoptosis. Dig Dis Sci. 48, 1284-91, 2003.
56. Yang, Q., Zhang, R., Wang, X.W., Linke, S.P., Sengupta, S., Hickson, I.D., Pedrazzi,
G., Perrera, C., Stagljar, I., Littman, S.J., Modrich, P., and Harris, C.C. The mismatch
DNA repair heterodimer, hMSH2/6, regulates BLM helicase in homologous DNA recombination.
Oncogene 23, 3749-3756, 2004.
57. Budhu, A.S., Zipser, B., Forgues, M., Ye, Q.H., Qin, L.X., Tang, Z.Y., Chen, Y.,
Simon, R., Sun, Z., Wang, X.W.: The Molecular signature of metastases of human
hepatocellular carcinoma. Toxicologic Pathology 32: 730-731, 2004
58. Hofseth LJ, Robles AI, Yang Q, Wang XW, Hussain SP, Harris C. p53: at the crossroads
of molecular carcinogenesis and molecular epidemiology. Chest 125, 83S-5S, 2004
59. Staib F, Robles AL, Varticovski L, Wang XW, Hussain P, Harris CC. P53-dependent gene
expression profiles in response to different types of cellular stress. Free radical
biology & medicine 37, S72-S73, 2004
60. Kim, J.W., Ye, Q.H., Forgues, M., Chen, Y., Budhu, A., Sime, J., Hofseth, L.J., Kaul,
R. and Wang, X.W.: Cancer-associated molecular signatures in the cirrhotic tissue samples
of patients with chronic liver disease. Hepatology 39, 518-27, 2004.
61. Ye, Q.H., Tang, Z.Y., Qin, L.X., Ma, Z.C., Wu, Z.Q., Ye, S.L., Liu, Y.Q., Fan, J.,
Wang, X.W. Application of genechip technology in identification of metastasis-associated
genes for hepatocellular carcinoma. Chin J Hepatobiliary Surg 10, 679-82, 2004.
62. Budhu, A.S., Zipser, B., Forgues, M., Ye, Q.H., Sun, Z., Wang, X.W.: The Molecular
signature of metastases of human hepatocellular carcinoma. Oncology 69 (S2), 2005.
63. Zhang, Y., Wang, X.W., Yu, M.H., Nakanishi, T., Kainate, D., Jelovic, D., Goulbeva,
O., Ross, D.D., Brodie, A. and Hamburger, A.W. The ErbB3 binding protein Ebp1 suppresses
androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Proc Natl Acad Sci USA 102, 9890-5, 2005.
64. Wang, W., Budhu, A., Forgues, M., and Wang, X.W. Temporal and spatial control of
nucleophosmin by the Ran/Crm1 complex in centrosome duplication. Nat Cell Biol 7, 823-30,
2005.
65. Budhu, A.S. and Wang, X.W. Loading and Unloading: Orchestrating Centrosome
Duplication and Spindle Assembly by Ran/Crm1. Cell Cycle 4, 150*-**-****.
66. Spillare, E.A., Wang, X.W. von Kobe, C., Bohr, V.A., Hickson, I.D. and Harris, C.C.
Redundancy of DNA helicases in p53-mediated apoptosis. Oncogene 25, 2119-23, 2006.
67. Staib F, Robles AI, Varticovski L, Wang XW, Sirotin N, Zhurkin VB, Hofseth LJ,
Hussain SP, Galle PR, and Harris CC: The p53 tumor suppressor network is a key responder
to microenvironment components of chronic inflammation stress. Cancer Res. 65, 10255-
10264, 2005.
68. Wu, C.G., Budhu, A., Chen, S., Zhou X., Ionescu, N.C., Valerie, K. and Wang, X.W.
Effect of Hepatitis C virus Core Protein on the Molecular Profiling of Human B lymphocyte.
Mol Med 12, 47-53, 2006.
67. Lambaa, J.K., Chen, X., Lan, L.B., Kim, J.W., Wang, X.W., Relling, M.V. Kazuto, Y.,
Watkins, P.B, Strom, S., Sun, D., Schuetz, J.D. and Schuetz, E.G. Increased CYP3A4 copy
number in TONG/HCC cells but not in DNA from other humans. Pharmacogenetics and Genomics
16, 415-427, 2006
68. Budhu, A., Forgues, M., Ye, Q.H., Jia, H.L., He, P., Zanetti, K.A., Kammula, U.S.,
Chen, Y., Qin, L.X., Tang, Z.Y., and Wang, X.W. Prediction of metastatic potential and
prognosis in hepatocellular carcinoma based on a unique immune response signature of the
liver microenvironment. Cancer Cell 10, 99-111, 2006.
69. Budhu, A and Wang, X.W. Role of cytokines in hepatocellular carcinoma. J. Leukocyte
Biology 80, 1197-213, 2006.
70. Lim, M.J. and Wang, X.W. Nucleophosmin and human cancer. Cancer Detection and
Prevention 30, 481-90, 2006.
71. Budhu, A and Wang, X.W. The role of nucleophosmin in Ran/Crm1-mediated centrosome
duplication. Center for Cancer Research Frontiers in Science, 5, 2006.
72. Jia, H.L., Ye, Q.H., Qin, L.X., Budhu, A., Forgues, M., Chen, Y., Liu, X.K., Sun,
H.C., Wang, L., Tang, Z.Y. and Wang, X.W. Gene Expression Profiling Reveals Potential
Biomarkers of Human Hepatocellular Carcinoma Including Those with Normal Serum Alpha-
Fetoprotein and Small Tumors. Clin Cancer Res, 13, 1133-9, 2007.
73. Takafuji, V.A., Forgues, M., Unsworth, E., Goldsmith, P., Wang, X.W. A 5-kD
osteopontin segment cleaved by matrix metalloproteinase-9 activity is essential for tumor
cell invasion in hepatocellular carcinoma. Oncogene, 26, 6361-71, 2007.
74. Hussain, S.P., Schwank, J., Staib, F., Wang, X.W., Harris, C.C. TP53 mutations and
hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Oncogene, 26, 2166-76, 2007.
75. Chen, X.C., Yu, B., Dong, J.C., Gu, Y.X., Chen, L., Wu, Q.Z., Hou, N.P., Liu, J.X.,
Xu, J.T., Jin, R.X., Jin, G.Q., Yang, X.D., Cao, Y.W., Tan, J.J., Zhu, B., Shen, J.C., Xu,
Z., Varticovski, L. and Wang, X.W. A Phase II Clinical Trial with Cytotropic Heterogeneous
Molecular Lipids (CHML") for Patients with Hepatic Malignancies. Anticancer Res, 27, 1593-
1600, 2007
76. Budhu, A., Chen, Y., Kim, J.W., Forgues, M., Valerie, K., Harris, C.C. and Wang, X.W.
Gene expression profiling of primary human hepatocytes expressing hepatitis C viral
proteins. Carcinogenesis, 28, 1552-60, 2007
77. Seike, M., Yanaihara, N., Bowman, E.D., Zanetti, K.A., Mechanic, L.E., Budhu, A.,
Kumamoto, K., Yokota, J., Gemma, A., Kudoh, S., Wang, X.W., Harris, C.C. A cytokine gene
signature of the lung environment predicts lymph node metastasis and prognosis of lung
adenocarcinoma. Journal of National Cancer Institute, 99, 1257-69, 2007.
78. Roessler, S, Budhu, A., Wang, X.W. The future of molecular profiling of human
hepatocellular carcinoma. Future Oncol, 3, 429-439, 2007
79. Yoshikawa, H., Matsubara, K., Zhou, X., Okamura, S., Kubo, T., Murase, Y., Shikauchi,
Y., Esteller, M., Herman, J.G., Wang, X.W., Harris, C.C. WNT10B functional dualism: b-
catenin/Tcf-dependent growth promotion or independent suppression with deregulated
expression in cancer. Mol Biol Cell, 18, 4292-303, 2007
80. Yamashita, T., Forgues, Budhu, A., Wang, X.W. Activation of hepatic stem cell marker
EpCAM by Wnt-b-catenin signaling in hepatocellular carcinoma. Cancer Res, 67, 10831-9,
2007
81. Budhu, A., Jia, H.L., Forgues, M., Liu, C.G., Goldstein, D., Lam, A., Zanetti, K.A.,
Ye, Q.H., Qin, L.X., Croce, C.M., Tang, Z.Y., Wang, X.W. Identification of metastasis-
related microRNAs in hepatocellular carcinoma. Hepatology, 47, 897-907, 2008
82. Yamashita, T., Forgues, M., Kim, J.W., Wang, W., Ye, Q.H., Jia, H.L., Budhu, A.,
Takafuji, V.A., Zanetti, K., Chen, Y., Qin, L.X., Tang, Z.Y., Wang, X.W. EpCAM and a-
fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.
Cancer Res, 68, 1451-61, 2008
83. Wang, R.H., Sengupta, K., Li, C., Kim, H.S., Cao, L., Xiao, C., Kim, S., Xu, X.,
Zheng, Y., Chilton, B., Zheng, Z.M., Wang, X.W., Ried, T., Deng, C.X. Impaired DNA damage
response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 14, 312-
23, 2008.
84. Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H., Jia, H., Ye, Q.,
Qin, L., Wauthier, E., Reid, L., Minato, H., Honda, M., Kaneko, S., Tang, Z., Wang, X.W.
EpCAM-positive hepatocellular carcinoma cells are tumor initiating cells with
stem/progenitor cell features. Gastroenterology, 136, 1012-24, 2009.
85. Wang, X.W. and Thorgeirsson, S.S. Transcriptome analysis of liver cancer: Ready for
the clinic? J Hepatology, 50, 1060-4, 2009.
86. Dong, F., Budhu, A., Wang, X.W. Translating the Metastasis Paradigm from Scientific
Theory to Clinical Oncology. Clin Cancer Res, 15, 2588-93, 2009.
87. Ji, J., Yamashita, T., Budhu, A., Forgues, M., Jia, H.L. Li, C., Deng, C., Wauthier,
E., Reid, L.M., Ye, Q.H., Qin, L.X., Yang, W., Wang, H.Y., Tang, Z.Y., Croce, C.M. and
Wang, X.W. Identification of MicroRNA-181 by Genome-Wide Screening as a Critical Player in
Epithelial C
Contact this candidate